GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Cyclically Adjusted FCF per Share

Medigen Biotechnology (ROCO:3176) Cyclically Adjusted FCF per Share : NT$-4.62 (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Medigen Biotechnology's adjusted free cash flow per share for the three months ended in Mar. 2025 was NT$-0.284. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is NT$-4.62 for the trailing ten years ended in Mar. 2025.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 8.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Medigen Biotechnology was 8.50% per year. The lowest was -2.50% per year. And the median was 0.70% per year.

As of today (2025-05-29), Medigen Biotechnology's current stock price is NT$31.00. Medigen Biotechnology's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was NT$-4.62. Medigen Biotechnology's Cyclically Adjusted Price-to-FCF of today is .


Medigen Biotechnology Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Medigen Biotechnology's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Cyclically Adjusted FCF per Share Chart

Medigen Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.10 -6.17 -6.02 -5.59 -4.73

Medigen Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.59 -5.33 -5.54 -4.73 -4.62

Competitive Comparison of Medigen Biotechnology's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Medigen Biotechnology's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Biotechnology's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Medigen Biotechnology's Cyclically Adjusted Price-to-FCF falls into.


;
;

Medigen Biotechnology Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medigen Biotechnology's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.284/134.9266*134.9266
=-0.284

Current CPI (Mar. 2025) = 134.9266.

Medigen Biotechnology Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -1.779 100.684 -2.384
201509 3.791 100.392 5.095
201512 -2.098 99.792 -2.837
201603 -2.248 100.470 -3.019
201606 -2.478 101.688 -3.288
201609 -1.854 101.861 -2.456
201612 -1.400 101.863 -1.854
201703 -0.939 102.862 -1.232
201706 -0.696 103.349 -0.909
201709 -0.945 104.136 -1.224
201712 -1.067 104.011 -1.384
201803 -1.269 105.290 -1.626
201806 -1.020 106.317 -1.294
201809 -1.046 106.507 -1.325
201812 -1.180 105.998 -1.502
201903 -2.001 107.251 -2.517
201906 -0.796 108.070 -0.994
201909 -0.611 108.329 -0.761
201912 -1.427 108.420 -1.776
202003 -1.233 108.902 -1.528
202006 -1.556 108.767 -1.930
202009 -1.536 109.815 -1.887
202012 -1.611 109.897 -1.978
202103 -1.203 111.754 -1.452
202106 -0.700 114.631 -0.824
202109 -2.040 115.734 -2.378
202112 6.619 117.630 7.592
202203 -0.850 121.301 -0.945
202206 -4.825 125.017 -5.207
202209 -4.038 125.227 -4.351
202212 0.435 125.222 0.469
202303 -0.106 127.348 -0.112
202306 -3.033 128.729 -3.179
202309 -0.733 129.860 -0.762
202312 -0.053 129.419 -0.055
202403 -0.205 131.776 -0.210
202406 -0.581 132.554 -0.591
202409 -0.375 133.029 -0.380
202412 1.060 133.157 1.074
202503 -0.284 134.927 -0.284

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Medigen Biotechnology  (ROCO:3176) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Medigen Biotechnology Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is a biopharmaceutical company engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The company has four segments: Nucleic acid department: segment, which derives maximum revenue, is responsible for services of testing reagents, instruments and inspection on behalf of others; New drug and vaccine research and development segment: responsible for the development and relevant services of new drugs and vaccine; Cytotherapy department: responsible for research and development and relevant services of cytotherapy; and Generic drug, aesthetic medicine product and dietary supplement segment is responsible for production and sales and relevant services of western medicine, aesthetic medicine product and dietary supplement.

Medigen Biotechnology Headlines

No Headlines